{"version":"1.0","type":"link","title":"Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.","author_name":"Yang Y 외","author_url":"https://prs-insight.online/author/Yang%20Y","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/170604","thumbnail_width":1200,"thumbnail_height":630}